Welcome to LookChem.com Sign In|Join Free
The company logo of Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Free supplier Enterprise Certification

Free
supplier
8th
years

Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Business Type:Lab/Research institutions

Audited Supplier

Main Products:
Year Established:
2017
Home>>Products>>E 7449

Products Categories

Product Certification&
Enterprise Certification

More Detail

Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Country: China (Mainland)

Business Type:Lab/Research institutions

E 7449

CAS NO.1140964-99-3

  • Min.Order: 1 Gram
  • Payment Terms:
Contact Supplier

Product Details

Keywords

  • E 7449
  • E7449
  • high purity and best price

Quick Details

  • ProName: E 7449
  • CasNo: 1140964-99-3
  • Molecular Formula: C18H15N5O
  • Appearance: white powder
  • Application: For laboratory use only- not intended ...
  • ProductionCapacity: 1 Kilogram/Month
  • Purity: ≥98%
  • Storage: room temperature
  • Transportation: by air
  • LimitNum: 1 Gram

Superiority

We are a CRO company, and our Research and Development team is consisted of PhDs and Masters in chemistry and pharmacy.

We are committed to protect our customer’s privacy with the highest level of ethical standard. Our dedicated team will follow up on every order and provide instant feedback on the status to our customer.

We stand behind our product by providing a complete QA report. The test data of customer order can be provided upon request.

We make our efforts to offer customer innovative, customized, high-quality service.

Our custom manufacturing encompasses everything from pharmaceutical intermediates to API.

 

 

 

Details

E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2; enhances the efficacy of radiotherapy and chemotherapy and has potent single agent anticancer activity in BRCA–deficient tumors. IC50 value: Target: PARP1/2 inhibitor E7449 is an orally bioavailable, potent, small molecule inhibitor of Poly(ADP–ribose) Polymerase (PARP)1 and PARP2. E7449 potently inhibits PARP1 and PARP2 in a cell–free assay and potentiates the cytotoxicity of both radiotherapy and chemotherapy. The cytotoxic effect of radiotherapy was enhanced by E7449 in clonogenic survival assays. The anti–tumor activity of the alkylating agent temozolomide was potentiated by E7449 in a dose responsive manner in vivo in the B16–F10 melanoma isograft mouse model. Daily dosing of E7449 as a single agent significantly inhibited tumor growth in a genetically engineered BRCA1 null mouse ovarian xenograft model. In the BRCA1 mutant human breast cancer cell line MDA–MB–436, E7449 significantly inhibited proliferation in a long term growth inhibition assay in vitro. Oral administration of E7449 once daily potently inhibited tumor growth in the MDA–MB–436 xenograft model with no toxicity observed. A dose responsive pharmacodynamic effect on PARP activity was demonstrated in MDA–MB–436 tumor tissue following administration of a single E7449 dose. The decrease in PARP activity was sustained over several hours. The ability of E7449 to inhibit PARP activity in tumor tissue was further investigated in the H460 xenograft model. Following single oral administration of various E7449 dosages, inhibition of PARP activity in tumor tissue was determined over time. Studies revealed that PARP is inhibited by E7449 in a time and dose dependent manner with lower doses resulting in transient inhibition and higher doses causing more complete and sustained PARP inhibition. Conclusion: E7449 is a potent and selective PARP1 and PARP2 inhibitor with potent anti–tumor activity in BRCA–deficient in vivo models. It also potentiates the activity of radiotherapy and chemotherapy pre–clinically. Evaluation of E7449 in a Phase 1 study will be initiated soon.
 
Hot Product